25,000 People Die Every Year from Drug-Resistant Infections in Europe, According to Biopharm Reports13 Jun 2013 • by Natalie Aster
Threats posed by the global increase in antibiotic resistant bacterial strains continue to cause alarm, and some observers suggest that this problem, caused by the use and misuse of antibiotics, is now threatening to take societies back to a pre-antibiotic era. In 2009, the World Health Organisation reported that in Europe 25,000 people die every year from drug-resistant infections. In the same year there were 440,000 new cases of MDR tuberculosis, in 69 countries.
Surveillance programmes such as The European Antimicrobial Resistance Surveillance System (EARSS) are tracking both the emergence and spread of resistance bacterial strains. In the case of EARSS, these include Streptococcus pneumoniae, Staphylococcus aureus, Enterococci, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. While the emergence of MRSA has embodied concerns over the rise of antibiotic resistance, other trends are becoming increasingly problematic. An example is the emergence of carbapenem resistance in K. pneumonia, due to a lack of alternative treatment options. Reports from the US suggest that 50–60% of all hospital-acquired infections are caused by antibiotic resistant bacteria, illustrating the human and financial impact of antibiotic resistance.
While the use of antibiotics has soared in recent decades, the approval of new antibiotics in the US fell by 60% from 30 during the decade 1983 to 1992, to just 12 over the period 1998 to 2009. Although recent years have seen a significant growth in the numbers and novelty of new pipeline antibiotics, it is evident that the health threats posed by antibiotic resistance need to be tackled urgently, and in many different ways.
This study investigated key areas in the clinic, as well as in the development of new antibiotics and bacterial diagnostics. It studied current and emerging integrated programs, that increasingly draw on local community findings of resistant and susceptible bacterial strains, as well as antimicrobial stewardships initiatives. This study involved the participation of experts in this field, who work daily on the challenges posed by antibiotic resistance.
In-demand report “Antibiotic Resistance 2013: A Global Market Study” by Biopharm Reports provides a wealth of information for companies and Government departments working in this field, and through a detailed analysis of the study’s findings, identifies commercial opportunities and provides insights, which will help to guide decision-making in this challenging field.
Antibiotic Resistance 2013: A Global Market Study
Published: February, 2013
Price: US$ 3,496.00
This global market study, which involved the participation of 652 clinicians, scientists, researchers and Government officials in 80 countries, provides a comprehensive review of current and evolving practices, developments and strategies in the combating and management of antibiotic resistance.
More information can be found in the report “Antibiotic Resistance 2013: A Global Market Study” by Biopharm Reports.
To order the report or ask for sample pages contact firstname.lastname@example.org